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Aims: To compare the policy positions of health and medical organisations across Australia, 
New Zealand, and the UK as they relate to sale and supply of nicotine vaping products (NVPs) 
and evaluate factors that have informed the differences in policy recommendations among 
these countries. 
Methods: We used mixed methods to analyse data from position or policy statements 
published by health and medical organisations regarding NVPs (n=30) and consultation 
documents submitted to government committees regarding policy options for the regulation of 
NVPs (n=26). Quality assessment of included documents was conducted using the six-item 
Joanna Briggs Institute (JBI) Critical Appraisal Checklist for Text and Opinion Papers, and 
findings were presented narratively. Qualitative data were coded using NVivo 12 software and 
analysed using thematic analysis. 
Results: An overwhelming majority of health bodies, charities and government agencies in the 
UK and New Zealand portrayed NVPs as a life-saving harm reduction tool. In contrast, 
concerns about addicting non-smoking youth to nicotine, a perceived lack of clear and 
convincing evidence of safety and efficacy and the potential to undermine tobacco control 
progress continues to define attitudes and recommendations towards NVPs among Australian 
health and medical organisations. Although the profoundly divided views among stakeholders 
seem to arise from empirical uncertainties and disagreements over the level and credibility of 
evidence, the source of most of these disagreements can be traced back to the fundamental and 
irreconcilable differences in the framing of the NVP debate, and varied tolerability of risk 
trade-offs associated with NVPs. 
Conclusion: Progress in resolving the controversy surrounding NVP policy requires 
stakeholders to be frame-reflective and engage in a meaningful dialogue of risk trade-offs, as 
well as both intended and unintended consequences of proposed policies.  








The nicotine and tobacco product landscape has seen unparalleled changes in the last decade 
due to rapid technological innovation and evolving regulatory environments. The popularity 
and widespread adoption of new nicotine delivery technologies (such as nicotine vaping 
products [or NVPs, exemplified by e-cigarettes] and heated tobacco products) among tobacco 
smokers as a way to quit and/or reduce harm from their nicotine use has challenged 
conventional tobacco control approaches based on promoting abstinence and opposing industry 
involvement. It has sparked a debate regarding the role of nicotine in smoking cessation and 
harm reduction efforts (Abrams et al., 2018; Farsalinos & Le Houezec, 2015; Glantz & 
Bareham, 2018). 
In general, the policy debate involves two main competing narratives (Green, Fielding, & 
Brownson, 2018). The first approach, exemplified by the UK and New Zealand, argues that 
because NVPs are likely to be much less harmful than combustible cigarettes, smokers who 
are unable or unwilling to quit should be encouraged to switch to these products to reduce their 
health risk. In the UK, the Medicines and Healthcare products Regulatory Authority (MHRA) 
initially announced it would regulate NVPs as a medicine. However, a dual regulatory pathway 
classifying NVPs as either a medicinal or a consumer product was finally adopted with the 
passing of the EU Tobacco Product Directive (TPD) in 2016 (The National Archives, 2016). 
Under the TPD, manufacturers may market NVPs that contain no more than 20mg/mL nicotine 
as either a consumer product or a medicine, while all products containing more than 20mg/mL 
must be licensed as medicines (European Commission, 2014). Only products licensed as 
medicines can make therapeutic claims, such as effectiveness for smoking cessation or health 
benefits. Similarly, in New Zealand, NVPs became legal to sell as a consumer product 
following the outcome of a court ruling in 2018 (The District Court of New Zealand, 2018). 
New Zealand is in the process of introducing new regulations for marketing NVPs as consumer 
products, while maintaining medicines regulation for NVPs with health claims.   
The second approach, demonstrated by Australia, contends that the introduction of any new 
product that carries unknown but potentially harmful effects should be prohibited until the 
safety and efficacy of the product is established with adequate certainty. Australia bans the use 
of nicotine in NVPs unless the user holds a valid medical prescription written by a registered 
medical practitioner (Gartner C & Bromberg M, 2019). Because there are no NVPs listed on 
the Australian Register of Therapeutic Goods, Australians can only access nicotine for use in 
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NVPs for a therapeutic purpose (e.g. quitting smoking) via one of the legal pathways for 
accessing unapproved therapeutic goods. This includes personal importation, the Special 
Access Scheme, Authorised Prescriber Scheme and extemporaneous compounding 
(Therapeutic Goods Administration, 2014). Non-therapeutic use of NVPs containing nicotine 
is prohibited. 
Although strong and unified advocacy by both government and non-government health 
agencies has played a significant role in advancing tobacco control policies, there are 
profoundly divergent standpoints when it comes to NVPs. This has resulted in a robust debate 
over the most appropriate regulatory framework (Green et al., 2018) and on what counts as 
evidence (Fairchild, Bayer, & Lee, 2019). The use of evidence in the health policymaking 
process is influenced by the interplay between a wide array of political and institutional factors 
including trade-offs between competing interests and priorities as well as ethical, financial and 
social justice considerations (Fallin-Bennett, Aleshire, Scott, & Lee, 2019). The process of 
evidence-based policymaking in NVP regulation is further complicated by the limited, and at 
times conflicting and contested bodies of evidence. A number of evidence-based reviews 
confirm that people who vape are exposed to fewer ‘harmful and potentially harmful 
chemicals’ than those who smoke (McNeill, Brose, Calder, Bauld, & Robson, 2018; National 
Academies of Sciences Engineering and Medicine, 2018; Royal College of Physicians, 2016). 
However, the evidence on the precise level of risk reduction possible from switching to NVPs 
is contested. A review of the evidence commissioned by Public Health England (PHE), which 
was updated in 2018, reaffirmed its previous estimate that NVPs are likely to be about 95% 
safer than conventional cigarettes (McNeill et al., 2018). While there is ongoing debate about 
the accuracy of this estimate due to reliance on a consensus study conducted with selected 
participants having potential conflicts of interests (Polosa, 2015), a consensus report from the 
National Academies of Sciences, Engineering, and Medicine (NASEM) concluded that “there 
is conclusive evidence that completely substituting NVPs for combustible tobacco cigarettes 
reduces users’ exposure to numerous toxicants and carcinogens present in combustible tobacco 
cigarettes”(National Academies of Sciences Engineering and Medicine, 2018). There is also 
continued debate about whether NVPs are an effective smoking cessation tool or if, by contrast, 
they might discourage smokers from becoming abstinent. In addtion there is the concern NVPs 
might encourage non-smokers to begin vaping, and even progress to smoking cigarettes. Lastly, 
the long-term health outcomes from use of NVPs is unknown (Abrams et al., 2018; Glantz & 
Bareham, 2018; Green et al., 2018). Amidst these divided views and empirical uncertainties, a 
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number of health and medical organisations have published their own position statements or 
practice guidelines about NVPs. Yet, the extent to which these policy papers and statements 
are evidence-based, non-biased, and are the result of an analytical process is not clear. The aim 
of this study was to compare and evaluate the policy positions of health and medical 
organisations across Australia, New Zealand, and the UK as they relate to sale and supply of 
NVPs. Specifically, this study aimed to: (1) compare the positions taken by the health and 
medical organisations of Australia to those in the UK and New Zealand which have adopted a 
more permissive regulatory framework; (2) evaluate factors that have informed the differences 
in policy discourse among these countries; and (3) evaluate what rationale and evidence were 
used to justify the regulatory positions adopted. 
Methods 
Data sources  
This study uses data from (1) position or policy statements published by health and medical 
organisations regarding NVPs and (2) submissions to government committees regarding policy 
options for the regulation of NVPs. Documents published by country-wide and/or federal level 
health bodies involved in health policymaking (including government agencies or legislators, 
non-profit health charities and professional health bodies) in the UK (England, Wales, Northern 
Ireland and Scotland), Australia and New Zealand were considered for inclusion. Technical 
and epidemiological reports, media releases and research articles were excluded. These 
countries were purposely selected to reflect the different policy frameworks in NVP 
regulations, with the UK having a supportive regulatory framework, Australia a highly 
restrictive regulatory approach and New Zealand a change from one that was similar to 
Australia to one more similar to the UK. The contrasting policy stances taken in these 
Commonwealth countries with very similar health systems, albeit based on the same body of 
literature, provides a unique opportunity to examine factors informing the differences in policy 
discourses and offers insights into the role of evidence in policymaking.  
Search strategy 
Three search strategies were employed in order to capture position statement published in the 
academic literature, as well as those only accessible in the grey literature. First, we searched 
five electronic databases (PubMed, EMBASE, PsycINFO, CINHAL, and Google scholar) for 
policy or position statements published in English from 2003 (to cover the literature from when 
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NVPs first entered the market) to June 12, 2019. This was followed by a Google search to 
further locate potential documents that were not captured by the scholarly database searches. 
The keywords used in the search strategy were organized to capture key concepts of the subject 
as ("E-cigarette" OR "E-cigarettes" OR "E-cig" OR "Electronic cigarette" OR "Electronic 
cigarettes" OR "Electronic Nicotine Delivery System" OR “Vaping" OR “Smoking”) AND 
(“Policy” OR “Statement” OR “Position” OR “Guideline”) AND “Association” OR 
“Department” OR “Council” OR “Foundation”). The detailed search strategy is presented in 
Figure 1.  
We also conducted a hand search of websites of relevant medical organisations and government 
agencies to identify relevant policy papers. We considered written consultation documents 
submitted by health and medical organisations to the following parliamentary committee 
inquiries (these are the most recent, comprehensive and nation-wide inquiries):  
1. The Australian House of Representatives Inquiry Into the Use and Marketing of 
E-cigarettes and Personal Vaporisers in Australia (2017) (Parliament of Australia, 
2017) 
2. The New Zealand Ministry of Health’s consultation on Policy Options for the 
Regulation of Electronic Cigarettes (August 2016) (New Zealand Ministry of 
Health, 2016) and  
3. The UK’s Science and Technology Committee (Commons) inquiry into the health, 
regulatory and financial implications of e-cigarettes (2017) (Science and 
Technology Committee (Commons), 2017) 
Four independent reviewers screened the records based on the eligibility criteria. Any 
discrepancies and/or disagreements between reviewers were resolved through discussion and 
consensus. Where the policy/position statement was not published in the last 12 months, 
contact was also made with the respective organisations requesting an up-to-date statement and 
if multiple versions of documents are available, the most recent one was included. The study 
protocol was registered on the International Prospective Register of Systematic Reviews 
(PROSPERO; CRD42019120203).  
We used mixed methods to understand the range of policy positions taken by health and 
medical organisations in these countries toward NVPs and to evaluate whether the policy 
stances were the result of an analytical process. Using a published tool, we examined the logic 
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of the opinion expressed, credibility and robustness of the source of the opinion and the extent 
to which alternative opinions or arguments were described and logically defended.  
 







We used the six-item Joanna Briggs Institute (JBI) Critical Appraisal Checklist for Text and 
Opinion Papers (Supplementary file 1) (McArthur, Klugárová, Yan, & Florescu, 2015). The 
JBI is an international, membership based research and development organization within the 
Faculty of Health Sciences at the University of Adelaide. The instrument was developed by the 
JBI before being reviewed by an international methodological group (McArthur et al., 2015). 
Testing was undertaken by group members working in pairs. In the case of the current paper, 
two authors independently appraised all documents as per JBI  criteria, and any disagreements 
raised were discussed and resolved through discussion and consensus with a third coder. 
Findings were then synthesised and presented narratively. Where there were sufficient data, we 
compared percentage agreement with each of the checklist items across countries. 
Data extraction and analysis 
Key policy recommendations and arguments made for and against adopting specific regulatory 
approaches were coded using NVivo version 12 software (QSR International Pty Ltd, 
Melbourne, Australia). The data were then qualitatively analysed using thematic analysis as 
per the procedures outlined by Braun and Clarke, which involves  (1) familiarizing with the 
data, (2) generating initial codes, (3) searching for themes, (4) reviewing themes, (5) defining 
and naming themes, and (6) producing the report (Braun & Clarke, 2006). Specifically, a line 
by line reading of included documents was first conducted to establish familiarity with the data. 
Guided by our research aims, a set of pre-specified (initial) codes were then generated which 
were merged into a higher level ‘themes’ based on similarity, representing a broader topic. In 
addition, an inductive approach was employed to identify new and emergent themes as we 
coded the data. A subset of the included documents were double coded independently by two 
authors. Any disagreements raised were discussed and resolved through consensus. The 
remaining documents were then coded by the first author, while both authors continued to meet 
throughout the coding process to make sure that coding criteria were being accurately and 
consistently applied. Other organisational attributes and document characteristics such as type 
of document (position statement, policy statement, and consultation document or practice 
guideline), year of publication as well as name and type of the organisation (professional health 
body, health charity, government health agency or others) were collected using a standardised 





Sample overview and stakeholder categories  
Thirty position/policy statements and 26 consultation documents were included in the analysis. 
Table 1 depicts the characteristics of included documents categorized by country. The majority 
of documents come from either professional societies (n=23) or not-for profit health charities 
(n=27) while the rest were from government health agencies (n=6). A list of the organisations 
and links to included documents is provided in supplementary file 1.  
 
Table 1. Characteristics of included documents, N=56 
 
Attributes  UK  Australia New Zealand Total, n (%) 
Type of document     
Position/policy statement 20 8 3 31 (55) 
Consultation document 4 6 15 25 (45) 
Sector*     
Peak health body 7 9 7 23 (41.1) 
Government agency 3 2 1 6 (10.7) 
Health charity 14 3 10 27 (48.3) 
Year of publication     
2013 1 - - 1 (1.8) 
2014 3 - - 3 (5.3) 
2015 2 1  3 (5.3) 
2016 3 1 15 19 (34) 
2017 9 8 1 18 (32) 
2018 4 4 2 10 (17.8) 
2019 2 - - 2 (3.6) 
 
Position statements from professional health bodies, health charities and government agencies 
contained a range of arguments for and against different regulatory approaches for NVPs. 
Statements from health and medical organisations in Australia consistently supported the 
current highly restrictive regulation of NVPs, apart from two professional organisations (Royal 
Australia and New Zealand College of Psychiatrists [RANZCP] and Drug and Alcohol Nurses 
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Australasia [DANA]). Thus, most Australian stakeholders advocated for maintaining the status 
quo which regulates NVPs as a prescription medicine if they contain nicotine, or as tobacco 
products if they do not contain nicotine. On the other hand, the overwhelming majority of those 
in the UK and New Zealand supported a permissive regulatory framework (consumer product 
regulation or a dual regulatory pathway). 
Although a number of rationales were put forward by opponents and proponents to justify the 
proposed regulatory recommendations, most differences centred on: (1) the policy objectives 
and framings that underpin the proposed regulatory frameworks, (2) what and how much 
evidence is needed for policymaking, and (3) consideration to and tolerability of various risk 
trade-offs. Although there were commonalities among stakeholders in the way these arguments 
were outlined, there were significant differences across countries which we discuss below. 
Policy objectives and framings 
Health and medical organisations in the UK and New Zealand presented NVPs as a life-saving 
harm reduction tool and stated that any regulatory framework governing nicotine containing 
products should aim to reduce the burden of smoking related death and diseases. They asserted 
that policies should consider the nicotine market as a whole and reflect the continuum of harm 
among all nicotine products. They recommended policies which  incentivised smokers to 
switch to less harmful nicotine containing products (such as nicotine replacement therapies 
[NRTs] and NVPs) while being discouraged from using the most harmful nicotine containing 
product (combustible cigarettes). This regulatory framework, often referred to as tobacco harm 
reduction, was portrayed as a coherent policy that complements national tobacco control 
agendas such as New Zealand’s Smoke free 2025 goal, and as an appropriate policy response 
that feeds into and contributes to achieving a ‘tobacco-free society’ [British Medical 
Association]. 
“The wide availability of e-cigarettes as an alternative to tobacco is likely, overall, to 
be playing a positive role in supporting tobacco-harm reduction, and consumer 
regulations will ensure a minimum standard of product quality.” British Medical 
Association, 2017 
 “The Ministry of Health believes vaping products have the potential to make a 
contribution to the Smoke free 2025 goal and could disrupt the significant inequities 




On the other hand, organisations in Australia have coalesced around a shared policy priority of 
protecting the health of specific ‘vulnerable’ populations (children, non-smokers and by-
standers). They argued that if NVPs are allowed to be freely marketed, they may undermine 
existing tobacco control efforts by renormalizing smoking as a socially acceptable behaviour, 
and increase youth smoking with a potential to addict a whole generation of youth to nicotine. 
This approach, often described as ‘precautionary’, was portrayed as consistent with various 
national and international health policy frameworks. Organisations that took this view argued 
that it takes Australia’s national circumstances into consideration, particularly the significant 
gains made in reducing smoking rates.  
“Regulation should aim to protect the Australian community from the potential harms 
of e-cigarette use and ensure that e-cigarette use does not undermine Australia’s 
significant tobacco control efforts.” Department of Health, Australia (Submission 297) 
 
“The Australian Government Department of Health believes a precautionary approach 
to e-cigarettes and personal vaporisers is warranted, consistent with the harm 
minimisation principles which underpin the National Tobacco Strategy (NTS) 2012-
2018 and Australia’s policy framework for other drugs.” Department of Health, 
Australia (Submission 297) 
The majority of joint health bodies representing members in both Australia and New Zealand 
(except RANZCP and DANA) have also supported a precautionary approach to NVP 
regulation. 
The role of evidence in NVPs regulation: Why, what and how much? 
What counts as evidence? 
Despite their countries having similar tobacco control policies and population smoking 
prevalence, the public health communities in the UK and New Zealand have come to starkly 
different positions compared to Australia. Nearly all stakeholders, regardless of type of 
organisations or policy positions being put forward, claimed that their policy was evidence-
based and cited relevant studies that supported their position. For instance, health and medical 
organisations in Australia generally cited evidence that strengthened their view that NVPs are 
a threat rather than an opportunity to public health. This scientific literature generally focused 
on the potential health risks associated with NVPs, for example: increased youth use of NVPs 
with a subsequent transition to cigarette smoking; dual use of NVPs and combustible cigarettes; 
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and concerns that NVPs could renormalise smoking and undermine tobacco control gains. 
Other potential health risks including concerns that NVPs are sustaining nicotine addiction and 
discouraging cessation attempts, adverse health effects of second-hand vapour exposure, and 
concerns of direct health harms including increased risk of respiratory and cardiovascular 
diseases were also widely cited.  
On the other hand, much of the evidence cited by UK stakeholders to support or rebut some of 
the most frequent arguments (e.g. whether NVPs are a way into or out of smoking, the potential 
for NVPs to renormalise smoking, and the potential health risk from second-hand vapour 
exposure) came from UK data. These collections of evidence generally reinforced the notion 
that most of these concerns have not yet materialised in the UK despite widespread vaping, and 
that youth and young adult smoking prevalence has declined while vaping prevalence has 
increased. It was based on these arguments that the majority of health bodies in the UK 
advocated to apply ‘a softer regulatory approach than exists for smoking in public.’ [British 
Medical Association] 
“There is no evidence that either NRT or e-cigarette use has resulted in renormalisation 
of smoking…None of these products has to date attracted significant use among adult 
never-smokers, or demonstrated evidence of significant gateway progression into 
smoking among young people.” Royal College of Physicians, 2016 
Regulation in the face of uncertainty: Wait for the evidence or Weight of the evidence? 
Whilst the need for long-term studies on the safety and efficacy of NVPs was universally 
acknowledged, stakeholders were divided when it came to how NVPs should be regulated in 
the context of growing but incomplete evidence. There were differing views on what was an 
adequate level of confirmatory evidence required before making any judgement or enacting a 
policy response. Stakeholders in the UK and New Zealand contended that while the long-term 
safety profile of NVPs remains uncertain, the currently available evidence base was sufficient 
to introduce a ‘cautious, yet pragmatic’ [New Zealand Medical Association] regulatory 
framework. The goal was to have NVPs available as a route out of smoking for current smokers 
without acting as a route into smoking for children and non-smokers. The Royal Australian and 
New Zealand College of Psychiatrists (RANZCP) reiterated the notion that the absence of long-
term evidence does not justify banning a product known to have substantially low risk 
compared to smoking.  
“Further research is required to ascertain the effectiveness of e-cigarettes and 
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vaporisers as tools for smoking cessation and whether they may provide a novel route 
into smoking initiation. This does not justify withholding what is, on the current 
evidence, a lower-risk product from existing smokers while such data is collected” 
RANZCP 
In contrast, all but two stakeholders in Australia [RANZCP and DANA] were in favour of 
maintaining the status quo, mainly on the basis that introduction of new products that carry 
unknown potentially harmful effects into the market before having confirmatory evidence of 
their safety and efficacy would be against the public’s best interest. Provision of such evidence 
and burden of proof that new products are safe and effective was argued to fall to stakeholders 
who want to see a change in the current regulations.  
 “The longitudinal research that is required to establish safety will take time, but until 
more definitive evidence on safety becomes available the precautionary principle 
should be applied to these products” Australian Medical Association (Written 
submission 289) 
“Health authorities and policy-makers should act to minimise harm to users and 
bystanders, and to protect vulnerable groups such as young people, until evidence of 
safety, quality and efficacy can be produced.” National Health and Medical Research 
Council (CEO statement), 2017 
 
Consideration to and tolerability of risk trade-offs 
Risk trade-offs 
Policy debates around NVP regulation have also highlighted various risk trade-offs associated 
with both allowing the sale of NVPs as a tobacco harm reduction tool and keeping NVPs off 
the market on the basis of a ‘precautionary principle’. Although the inherent nature of risk 
trade-offs was universally recognised, the tolerability of these trade-offs appeared to vary 
between countries. Stakeholders in Australia emphasised the concern that NVPs have the 
potential to addict non-smoking youth to nicotine and framed them as one of the tobacco 
industry’s tactics to influence and resist tobacco control policy and undermine progress in 
tobacco control.  
“Concerns have been raised that the potential benefits of e-cigarettes in reducing harm 
to smokers may be outweighed by the risks that they may undermine tobacco control 
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efforts.” National Health and Medical Research Council (CEO statement), 2017 
As such, jeopardising the lives of young people for adult smokers to have access to these 
products was portrayed as an unacceptable risk trade-off. Potential adverse impacts and 
unintended consequences of the current approach were seldom addressed by those referencing 
the precautionary principle. 
In contrast, those who placed tobacco harm reduction at the centre of their policy objectives 
(such as those in the UK) characterised NVPs as novel nicotine delivery technologies that 
might lead to a dramatic decline in the use of combustible cigarettes. They stated that promoting 
use of NVPs among smokers is ‘in the interests of public health’ [Royal College of Physicians 
(RCP)]. RCP argued that following an overly cautious regulation may cause more harm than 
benefit and that this was associated with the unacceptable trade-off of perpetuating smoking.  
 
“A risk-averse, precautionary approach to e-cigarette regulation can be proposed as 
a means of minimising the risk of avoidable harm. However, if this approach also makes 
e-cigarettes less easily accessible, less palatable or acceptable, more expensive, less 
consumer friendly or pharmacologically less effective, or inhibits innovation and 
development of new and improved products, then it causes harm by perpetuating 
smoking.” RCP (Royal College of Physicians, 2016) 
 
Similarly, the public health community in New Zealand emphasised the potential benefits of 
NVPs and the unintended consequences of restrictive regulation in advocating a ‘cautious, yet 
pragmatic’ regulatory approach. This approach was portrayed as encouraging smokers to 
switch to vaping, but also giving due emphasis to the potential risk of uptake by children and 
non-smokers. Examples of specific controls advocated to deter access to NVPs by children and 
young adults included prohibiting sale to minors (aged 18 or below), prohibiting sale in vending 
machines and banning point of sale displays. 
Quantifying relative risk 
Although the notion that NVPs are less harmful compared to combustible tobacco products 
was universally acknowledged, there was debate over the precise level of risk reduction and 
the extent of health gains possible from switching to NVPs compared to abstinence. An 
overwhelming majority of organisations from the UK and New Zealand reiterated the Public 
Health England’s (PHE) updated evidence review that reaffirmed its previous estimate that 
NVPs are about ‘95% safer than conventional cigarettes’ (McNeill et al., 2018) or RCP’s 
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independent review that concluded the long term health risk of NVPs is ‘unlikely to exceed 5% 
of the harm from smoking tobacco’(Royal College of Physicians, 2016). This ‘less harmful 
than combustible cigarettes’ argument is based on the notion that the use of nicotine per se 
carries negligible health risk, and that it is the other constituents of tobacco smoke (tar, 
particulate matter and gases such as carbon monoxide) that cause most of the harm. This puts 
the potential health risks associated with NVPs in the context of the substantial harm associated 
with smoking. 
In contrast, those who were in favour of a highly restrictive regulatory approach argued that 
NVPs ‘MAY be less harmful than cigarettes, but they are NOT HARMLESS’ [The Thoracic 
Society of Australia and New Zealand and Lung Foundation Australia, Written submission 
332], and some stated that there is no safe level of exposure to nicotine (be it from combustible 
cigarettes or NVPs), particularly for young adults. Rather than making combustible cigarettes 
a point of reference against which the safety of other nicotine containing products are 
compared, advocates of restrictive regulation argued that the safety of NVPs must be 
considered in the context of abstinence (quitting or not taking up any nicotine use). They 
framed safety related discussions by the absolute term ‘safe’, rather than the relative term 
‘safer’.  
 “Evidence shows there are only two effective ways to minimise the long-term harms of 
smoking – to quit or to avoid take-up” Cancer Council Australia and National Heart 
Foundation of Australia, Written submission 295 
It was also argued that the current scientific evidence is insufficient to put a specific figure 
about how much safer NVPs are compared to combustible cigarettes. With this, PHE’s ‘95% 
safer than smoking’ estimate was criticised and labelled as ‘unfounded and devoid of any 
scientific basis’ [Cancer Council Australia and National Lung Foundation of Australia Written 
submission 295]. 
Specific regulatory options recommended 
Specific regulatory measures that stakeholders mentioned included regulating packaging and 
labelling, quality standards, sale and supply, as well as banning vaping in smoke-free areas. 
The need to prevent minors and non-smokers from accessing NVPs was frequently discussed 
and universally agreed on by stakeholders, irrespective of the positions being taken on NVP 
regulation. Prohibiting the sale of NVPs to people aged 18 or below, and prohibiting vending 
machine sales were some of the policy measures recommended to prevent uptake by children 
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and young adults. There was also a general consensus that NVPs should not be advertised or 
marketed in a way that would appeal to children and non-smokers. The current UK restrictions 
(under EU TPD regulations) were considered sufficient by the majority of UK organisations.  
“The current regulatory framework appears sufficient for addressing concerns about 
the use of e-cigarettes by children and young people, for whom regular use remains 
low and is largely confined to those that have already smoked.” BMA, 2017 
However, the public health community in Australia consistently advocated applying the 
marketing and advertising restrictions of the Tobacco Advertising Prohibition Act 1992 to 
vaping products. This Act prohibits all types of promotion, advertising, free distribution, 
sponsorship and point-of-sale display. 
All but two stakeholders in Australia [RANZCP and DANA] advocated prohibiting use of 
NVPs, with or without nicotine, in smoke-free areas. Some health charities also recommended 
that vaping should be prohibited in legislated smoke free areas ‘even if ultimately approved by 
the TGA for therapeutic use.’ [Australian Council on Smoking and Health, written submission 
285]. An exception to this, however, was the policy statement published submission made by 
RANZCP, which recommended allowing the use of NVPs in smoke-free mental health 
facilities. 
“The RANZCP also notes that many mental health facilities are now smoke-free and 
there may be benefits in allowing the use of e-cigarettes and vaporisers in these 
settings.” RANZCP written submission 294. 
Some stakeholders in the UK and New Zealand pointed out the lack of evidence for harm from 
exposure to second-hand vapour, and suggested that businesses and local authorities should 
make reasoned decisions on whether to allow NVPs in their premises on a case-by-case basis.  
“Unless we start to see rising youth smoking rates, rising regular e-cigarette use among 
‘never smokers,’ or any convincing evidence for harm to bystanders, it is difficult to 
justify a blanket ban on e-cigarette use in indoor public places.” Cancer Research UK 
Table 2 shows the results from the JBI tool. Irrespective of country, all the documents clearly 
identified their sources (Question 1), had demonstrated standing in the field of expertise 
(Question 2) and focussed on the interests of the relevant population (Question 3).  However, 
where it was possible to assess, 8 out of 14 Australian documents (57%) did not explain the 
analytical process and logic in the opinion expressed, as opposed to 3 out of 12 New Zealand 
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publications (25%) and 5 out of 24 UK statements (21%) (Question 4). Similarly, 11 out of 14 
Australian documents did not reference the extant literature (85%), compared to 5 out of 24 
(45%) of those from the UK (Table 2). Finally, the practice of making strong assertions based 
on incomplete evidence was more common among stakeholders in Australia (11 out of 14) than 
the UK (10 out of 22) (85% vs 43% respectively) (Question 6) (Table 2). There were 




Table 2: Results of critical appraisal of included documents using the JBI Critical Appraisal Checklist for Text and Opinion Papers 






Q3: Interests of 
relevant population 
the central focus? 
Q4: Analytical 
process & logic in the 
opinion expressed? 







      
Action on Smoking and Health UK 1 1 1 1 1 1 
Association for Respiratory 
Technology and Physiology 
1 1 1 1 NA NA 
British Lung Foundation 1 1 1 1 1 1 
British Medical Association 1 1 1 1 1 1 
British Psychological Society 1 1 1 1 1 1 
British Thoracic Society 1 1 1 1 0 0 
Cancer Research UK 1 1 1 1 1 1 
Institute of Health Promotion and 
Education 
1 1 1 0 0 0 
Pharmacists’ Defence Association 1 1 1 0 0 0 
Primary Care Respiratory Society 
UK 
1 1 1 1 
 
0 0 
Public Health England 1 1 1 1 1 1 
Royal College of General 
Practitioners 
1 1 1 1 
 
NA 1 
Royal College of Physicians 1 1 1 1 1 1 
Royal College of Psychiatrists 1 1 1 1 1 1 
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Royal Pharmaceutical Society 1 1 1 1 0 0 
Royal Society for Public Health  1 1 1 1 1 1 
Smoking in Pregnancy Challenge 
Group 
1 1 1 1 1 1 
UK Centre for Tobacco and 
Alcohol Studies 
1 1 1 1 1 1 
NHS Health Scotland  1 1 1 1 0 0 
Scottish Directors of Public Health 
and Scottish Health 
1 1 1 0 0 0 
NI Chest Heart and Stroke 1 1 1 0 0 0 
Pharmaceutical Society of 
Northern Ireland 
1 1 1 0 0 0 
ASH Wales 1 1 1 1 0 0 
Public Health Wales 1 1 1 1 1 
 
0 
Australia       
Australian Council on Smoking 
and Health  
1 1 1 0 0 0 
Australian Dental Association 1 1 1 0 0 0 
Australian Medical Association  1 1 1 1 NA 1 
Cancer Council Australia and 
Heart Foundation Australia 
1 1 1 1 1 1 
Cancer Australia 1 1 1 0 0 0 
Drug and Alcohol Nurses of 
Australasia  
1 1 1 0 0 0 
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Department of Health 1 1 1 1 0 1 
National Health and Medical 
Research Council  
1 1 1 1 0 1 
Public Health Association of 
Australia 
1 1 1 0 0 1 
Royal Australasian College of 
Physicians** 
1 1 1 1 1 1 
Royal Australasian College of 
Surgeons** 
1 1 1 0 0 0 
Royal Australian and New 
Zealand College of Psychiatrists**  




Royal Australian College of 
General Practitioners** 
1 1 1 0 0 0 
Thoracic Society of Australia and 
New Zealand & Lung Foundation 
Australia** 
1 1 1 0 0 1 
New Zealand  
      
Action on Smoking and Health NZ 1 1 1 NA NA NA 
Asthma and Respiratory 
Foundation NZ 
1 1 1 0 0 0 
Cancer Society of NZ 1 1 1 1 0 1 
End Smoking NZ  1 1 1 1 1 1 
Heart Foundation NZ 1 1 1 NA NA NA 
Lung Foundation NZ 1 1 1 NA NA NA 
Ministry of Health 1 1 1 1 1 1 
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New Zealand Drug Foundation 1 1 1 1 1 1 
New Zealand Medical Association 1 1 1 0 NA NA 
New Zealand Nurses 
Organisation 
1 1 1 1 NA NA 
Pharmaceutical Society of New 
Zealand 
1 1 1 1 NA NA 
Pharmacy Guild of New Zealand 1 1 1 0 NA NA 
Public Health Association of New 
Zealand 
1 1 1 1 NA NA 
Smoke-free Nurses Aotearoa 
New Zealand  
1 1 1 1 NA NA 
Stroke Foundation of New 
Zealand 
1 1 1 1 NA NA 
*1: Yes; 2: No; NA: Not Applicable  






In this study, we examined the policy positions of professional health bodies, health charities and 
government agencies across Australia, New Zealand, and the UK as they relate to sale and supply 
of NVPs. It was evident from findings from this study that the public health communities in the 
UK and New Zealand have come to starkly different conclusions regarding the role of NVPs 
compared to Australia. Although the profoundly divided views among the public health 
community seem to arise from empirical uncertainties and disagreements over the level and 
credibility of evidence, the source of some of these disagreements can be traced back to the 
fundamental and irreconcilable differences in the framing of the NVP debate, which in turn 
influences their use of evidence. The type and credibility of evidence that was given greater 
weight in policymaking appeared to be contingent, at least partially, on the way the issue was 
framed and understood. Analysis of how the literature was cited (using the JBI checklist) 
indicated that this was often a non-critical description of corroborating evidence explicitly 
supportive of the assertion being put forward, while conflicting evidence was not addressed. In 
doing so, they tend to cite a fraction of the evidence or interpret the evidence differently. This 
was apparent from analysis of the cited literature (within each position or policy documents) in 
that most of the assertions made were based on strategic use of evidence, citing only evidence 
that corroborates the arguments being put forward. 
Some of the prominent health bodies included in this study (such as Royal Australasian College 
of Surgeons, Royal Australian and New Zealand College of Psychiatrists, Thoracic Society of 
Australia and New Zealand and Royal Australasian College of Physicians) are joint organisations 
that represent members in both Australia and New Zealand. Although these health bodies are 
actively involved in the policy debates in both countries and submitted consultation papers 
having similar sentiments, these neighbouring countries have adopted different policy 
approaches to the regulation of nicotine and NVPs. The Ministry of Health and other health 
officials in New Zealand have not only endorsed a role for NVPs in reducing tobacco related 
harm, but are also proactively encouraging smokers to switch to vaping, and supporting stop 
smoking services to become ‘vaping friendly’ (New Zealand Ministry of Health, 2019). The 
Commonwealth Department of Health in Australia, on the other hand, supports a restrictive 
regulatory framework and insists that the approach is ‘evidence-based’ and ‘relevant to 
Australia’s national circumstances’ (Department of Health, 2018). These differences 
demonstrate how existing tobacco control policies and differences in policy styles between 
countries inform NVP related debates. 
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The concept of risk trade-offs is central to various decision-making theories (Amalberti, 2013) 
and is also inherent in NVP regulation. Yet, consideration and tolerability of these trade-offs 
appeared to vary between countries. For instance, while stakeholders in Australia agreed that 
NVPs are less harmful compared to combustible cigarettes, putting vulnerable populations 
(children and non-smokers) at any risk for adult smokers to have access to these products was 
portrayed as an unacceptable risk trade-off. The potential detrimental consequences (such as 
perpetuating smoking among both adults and youth), however, was seldom addressed by those 
referencing the ‘precautionary principle’. This suggests much greater weight was given in 
Australia to potential risk to current non-smokers over potential benefit to smokers (Erku, 
Morphett, Steadman, & Gartner, 2019). Furthermore, it also suggests that maintaining the status 
quo is seen as the lower risk policy option, but without considering the potential risks of this 
policy. The net public health gain or loss from NVP use will ultimately be contingent on the 
regulatory framework adopted, with the highest benefit most likely to be realised if non-smoking 
youth are protected from taking up NVPs while persistent smokers are encouraged to switch.  
Recent studies suggest that the use of research evidence in developing policy largely depends on 
wider socio-political priorities (Hawkins & Ettelt, 2019; Rein & Schön, 1996; Sohn, 2018). 
Understanding this process is, therefore, central to resolving disputes especially in areas that 
involve contested policy arenas, vehement debates and multiple stakeholders. A number of case 
studies on framing and use of evidence in health policy making has been published in different 
country contexts (Parkhurst, Ettelt, & Hawkins, 2018). While our study mainly examined reasons 
for differences in NVP-related policy between these countries, it also offers insights into the role 
of evidence and framing in policymaking. The notion that NVP-related policymaking should be 
informed by evidence was widely accepted, and often discussed amongst stakeholders in these 
countries, regardless of their stances on the issue of NVPs. However, what was portrayed as 
disagreements over the level and credibility of evidence were often actually differences in wider 
priorities and the acceptability of various risk trade-offs. This finding reinforces the notion that 
so-called evidence-based policymaking goes beyond a dispassionate evaluation of the evidence, 
but is instead influenced by a wide array of political and institutional factors. A frame-reflective 
policy conversation could therefore help resolve the debate concerning these products (Rein & 
Schön, 1996). This acknowledges that contentious policy issues may be understood in different 
ways by different stakeholders based on competing priorities. Such meaningful policy 
conversations would ensure the consideration of both intended and unintended consequences of 
current and proposed policies (Rein & Schön, 1996).  
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Study limitations  
This study has a number of limitations that should be taken into account while interpreting the 
findings. Although we have employed rigorous and multiple approaches to identify and include 
all relevant documents, it is possible that we missed some position/policy statements that were 
not published or not made publicly available. As we have only included the most recent and 
updated statement from each organisation (if multiple versions of documents or updates were 
available), our study did not reflect or examine how their positions have changed over time. 
Although the written consultation documents included in our study were retrieved from the most 
recent nation-wide parliamentary inquiries (at the time of conducting this study), it was difficult 
to apply some of the items in the JBI appraisal tool to these documents. This was particularly the 
case for the New Zealand inquiry, where submissions most often consisted of structured 
responses to specific questions from the inquiry, which did not ask organisations to provide 
supporting evidence or references. The JBI instrument is in continual development and so 
resultant findings should be seen as preliminary. Hence, we have given greater prominence to 
the qualitative results. Finally, this study should be regarded as a snapshot, as the science 
surrounding NVPs is evolving. These include the possible effects of recent increases in nicotine 
concentration in some products in the United States. However, this does not yet apply to the UK 
where concentrations cannot exceed 2%. In addition, our review does not reflect emerging 
reports, again in the United States, concerning e-cigarette, or vaping, product use–associated 
lung injury (EVALI) (Navon et al., 2019). However, the overwhelming number of cases appear 
to have followed the use of black-market THC cartridges, possibly related to the addition of 
vitamin E acetate, rather than commercially produced NVPs (Navon et al., 2019; Taylor, 2019). 
Conclusion 
An overwhelming majority of health bodies, charities and government agencies in the UK and 
New Zealand presented NVPs as a life-saving harm reduction tool and supported a regulatory 
framework that would incentivise smokers to switch to them as a less harmful nicotine containing 
product. In contrast, concerns about addicting non-smoking youth to nicotine, a perceived lack 
of clear and convincing evidence of safety and efficacy and the potential to undermine tobacco 
control progress continues to define scepticism towards NVPs among Australian health and 
medical organisations. Although stakeholders from both sides of the argument claimed their 
position to be evidence-based and cited relevant literature that corroborated their arguments, 
fundamental differences in the policy objectives and framings that underpin the proposed 
regulatory frameworks and consideration to and tolerability of various risk trade-offs were at the 
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centre of the disagreements. Progress in resolving the debate surrounding NVPs require policy 
makers to be frame-reflective and engage in a meaningful dialogue which gives due 
consideration to various risk trade-offs and both intended and unintended consequences of 
proposed policies. 
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